Compare BNZI & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNZI | APVO |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 21.7M |
| IPO Year | N/A | N/A |
| Metric | BNZI | APVO |
|---|---|---|
| Price | $1.01 | $0.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | 395.5K | ★ 1.8M |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,650,176.00 | N/A |
| Revenue This Year | $205.97 | N/A |
| Revenue Next Year | $31.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.06 | N/A |
| 52 Week Low | $0.94 | $0.50 |
| 52 Week High | $27.00 | $109.80 |
| Indicator | BNZI | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 35.09 | 21.84 |
| Support Level | $0.94 | $1.00 |
| Resistance Level | $1.08 | $1.11 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 15.48 | 10.67 |
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.